Srinivasan says enrolling patients in clinical trials that best represents their type of kidney cancer is an appropriate course of action for treatment.
Ramaprasad Srinivasan, MD, PhD
Advertisement
Articles by Ramaprasad Srinivasan, MD, PhD
Advertisement
Latest Updated Articles
Dr. Ramaprasad Srinivasan on the Complex Heterogeneity of Kidney CancerPublished: January 16th 2016 | Updated:
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5
